Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $29.00

Key Points

• Astria Therapeutics, Inc. has received an average rating of "Buy" from seven analysts, with five recommending a buy and two a strong buy, aiming for a 12-month target price of $29.00.
• Institutional investors hold 98.98% of Astria Therapeutics' stock, with Deutsche Bank AG increasing its holdings by 54.3% in the latest quarter.
• The company's recent quarterly earnings report showed a loss of ($0.58) earnings per share, missing estimates by ($0.10), as analysts predict a projected loss of -1.65 EPS for the current fiscal year.

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has earned an average rating of "Buy" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $29.00.

Several equities research analysts have weighed in on ATXS shares. HC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Friday, June 13th. Cantor Fitzgerald restated an "overweight" rating and issued a $47.00 target price on shares of Astria Therapeutics in a research note on Wednesday, May 14th.

Institutional Trading of Astria Therapeutics

Institutional investors have recently modified their holdings of the stock. KLP Kapitalforvaltning AS purchased a new stake in shares of Astria Therapeutics during the 4th quarter valued at approximately $41,000. Tower Research Capital LLC TRC increased its stake in Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock worth $47,000 after buying an additional 2,766 shares during the period. Farther Finance Advisors LLC increased its stake in Astria Therapeutics by 185.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company's stock worth $29,000 after buying an additional 3,557 shares during the period. BNP Paribas Financial Markets purchased a new stake in Astria Therapeutics during the 4th quarter worth approximately $50,000. Finally, Virtus ETF Advisers LLC purchased a new stake in Astria Therapeutics during the 4th quarter worth approximately $65,000. Institutional investors and hedge funds own 98.98% of the company's stock.

Astria Therapeutics Price Performance

ATXS stock traded down $0.36 during mid-day trading on Friday, reaching $6.56. The company had a trading volume of 233,456 shares, compared to its average volume of 229,657. The company has a market capitalization of $370.18 million, a PE ratio of -3.51 and a beta of 0.47. The firm has a 50 day moving average of $5.84 and a 200 day moving average of $5.82. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.10). Analysts anticipate that Astria Therapeutics will post -1.65 EPS for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.